Retinal biomarkers move cardiovascular risk screening toward the eye
Oculomics has moved from a conceptual sideline to a serious cardiovascular research question. This review brings together evidence from retinal vascular morphology, structural and perfusion imaging, retinal aging, metabolomics, and artificial intelligence models that connect retinal signals with cardiovascular risk factors, subclinical disease, clinical events, and cardiorenal and metabolic outcomes. The central idea is clinically intuitive: the retina offers a direct, noninvasive view of microvascular health, and microvascular injury often travels with systemic vascular disease long before symptoms declare themselves.
A single retinal image can contain far more information than a routine screening photograph suggests. Vessel caliber, branching geometry, tortuosity, perfusion patterns, and age-related structural changes may all reflect the burden of hypertension, diabetes, endothelial dysfunction, and small-vessel injury. When those features are extracted by artificial intelligence, they can be combined into risk signatures that are not visible to the naked eye. The promise is not diagnostic spectacle. It is earlier risk recognition in patients who may otherwise be labeled low risk by conventional scoring alone.
One sentence captures the tension in the field: the biology is plausible, but the clinical utility is still unproven.
Why the retina may mirror vascular disease elsewhere
The retinal circulation is uniquely suited to biomarker work because it is accessible, reproducible, and tightly coupled to systemic hemodynamics. Chronic pressure load, glycemic injury, and inflammatory remodeling can alter small vessels in ways that are measurable on fundus photography, optical coherence tomography, and perfusion-based imaging platforms. In practical terms, the retina behaves like a visible extension of the body’s microcirculation, which is why it has become attractive for cardiovascular phenotyping.
The review links these retinal patterns to broader cardiorenal and metabolic outcomes as well. That matters because cardiovascular risk is rarely isolated to one organ. Kidney disease, diabetes, and heart disease often progress together through shared endothelial and microvascular pathways, and retinal biomarkers may help capture that shared biology without blood draws or invasive testing. In this framework, the eye is not replacing the heart, kidneys, or laboratory evaluation; it is adding a window into the same disease process from a different angle.
AI gives this approach scale. Traditional retinal interpretation depends heavily on expert grading and predefined measurements. Machine learning systems can mine thousands of image features simultaneously, potentially identifying composite patterns that track with future cardiovascular risk more effectively than any single geometric measurement. Such models may also integrate retinal aging signals and metabolomic associations, broadening the biomarker concept beyond vessel appearance alone.
From image features to cardiovascular prediction
The review places retinal biomarkers in a spectrum that runs from morphology to event prediction. At one end are structural descriptors such as vessel width, branching patterns, and retinal aging signatures. At the other are links with clinical events and end-organ outcomes. Between those poles sits the current translational challenge: separating a signal that is statistically associated with disease from a biomarker that changes management.
That distinction is not trivial at the bedside. A retinal risk score that identifies vulnerability earlier could influence how aggressively clinicians pursue blood pressure control, lipid lowering, glucose management, and follow-up intensity. Yet the review is careful not to overstate the current evidence. These biomarkers may complement conventional risk assessment, but no routine cardiovascular pathway should be built around them until their predictive value is validated prospectively across real-world populations.
Interpretability remains central. If an algorithm flags a patient as high risk, clinicians need to know what retinal feature drove the result, how robust that signal is across devices and populations, and how much it adds beyond established cardiovascular risk tools. Without that transparency, adoption will stall in both ophthalmology and cardiology.
Standardization will determine whether oculomics leaves the lab
The review is direct about the obstacles. Prospective validation is still needed. Standardized acquisition is still needed. Interoperability is still needed. Interpretability is still needed. Equitable evaluation is still needed.
Those requirements are more than administrative preferences. Retinal imaging systems differ across vendors, image quality varies by patient and setting, and analysis pipelines may not transport cleanly from one clinic to another. An algorithm trained in one population can fail in another if disease prevalence, ancestry, ocular comorbidity, or image acquisition standards differ. In cardiovascular medicine, where risk tools are judged by calibration as much as discrimination, that kind of instability can blunt clinical usefulness quickly.
Equity deserves special attention. Retinal biomarkers should be evaluated in populations that reflect the diversity of cardiovascular disease, not only in curated datasets with ideal image quality. If an AI model performs well in one group and poorly in another, it risks widening disparities rather than reducing them. The authors’ emphasis on equitable evaluation is therefore not an afterthought; it is a prerequisite for any future screening strategy.
Digital twins remain a concept, not a clinical workflow
The review also places retinal biomarkers within the idea of cardiovascular digital twins. In theory, retinal data could feed personalized computational models that integrate imaging, clinical history, laboratory values, and physiologic parameters to simulate risk trajectories. The concept is compelling because it could transform static risk scoring into dynamic personalization.
For now, though, digital twin integration remains conceptual. No current evidence base is strong enough to support routine deployment of retinal biomarkers inside a clinical simulation framework for cardiovascular decision-making. The field still needs longitudinal cohorts, external validation, reproducible thresholds, and demonstration that retinal AI changes outcomes rather than merely producing more data.
A narrow but important clinical message emerges from the review: the eye may become a practical source of cardiovascular intelligence, but only if the field proves that image-derived signals are reproducible, interpretable, and actionable. Until then, retinal biomarkers remain a promising adjunct to established risk assessment, not a substitute for it.